ARTELO BIOSCIENCES INC (ARTL)
US04301G5080 - Common Stock
Taking everything into account, ARTL scores 2 out of 10 in our fundamental rating. ARTL was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of ARTL is average, but there are quite some concerns on its profitability. ARTL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ARTL has reported negative net income.
In the past year ARTL has reported a negative cash flow from operations.
ARTL had negative earnings in each of the past 5 years.
In the past 5 years ARTL always reported negative operating cash flow.
1.2 Ratios
ARTL has a Return On Assets of -127.82%. This is amonst the worse of the industry: ARTL underperforms 83.25% of its industry peers.
The Return On Equity of ARTL (-143.39%) is worse than 65.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -127.82% | ||
| ROE | -143.39% | ||
| ROIC | N/A |
ROA(3y)-59.81%
ROA(5y)-63.82%
ROE(3y)-64.26%
ROE(5y)-70.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ARTL has been increased compared to 1 year ago.
ARTL has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ARTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -10.42, we must say that ARTL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.42, ARTL is doing worse than 75.92% of the companies in the same industry.
There is no outstanding debt for ARTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.42 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ARTL has a Current Ratio of 7.15. This indicates that ARTL is financially healthy and has no problem in meeting its short term obligations.
ARTL has a better Current ratio (7.15) than 75.92% of its industry peers.
A Quick Ratio of 7.15 indicates that ARTL has no problem at all paying its short term obligations.
ARTL has a Quick ratio of 7.15. This is in the better half of the industry: ARTL outperforms 76.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.15 | ||
| Quick Ratio | 7.15 |
3. Growth
3.1 Past
ARTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.31%, which is quite good.
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, ARTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.71% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.77%
EPS Next 2Y31.8%
EPS Next 3Y21.9%
EPS Next 5Y13.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ARTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ARTL's earnings are expected to grow with 21.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.8%
EPS Next 3Y21.9%
5. Dividend
5.1 Amount
No dividends for ARTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARTELO BIOSCIENCES INC
NASDAQ:ARTL (12/20/2024, 8:00:01 PM)
After market: 0.95 +0 (+0.25%)0.9476
+0 (+0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.7%
Inst Owner Change-12.22%
Ins Owners29.04%
Ins Owner Change0%
Market Cap3.06M
Analysts84
Price Target14.28 (1406.96%)
Short Float %1.03%
Short Ratio1.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.55%
Min EPS beat(2)13.15%
Max EPS beat(2)25.94%
EPS beat(4)3
Avg EPS beat(4)-4.14%
Min EPS beat(4)-83.16%
Max EPS beat(4)27.52%
EPS beat(8)5
Avg EPS beat(8)-6.04%
EPS beat(12)7
Avg EPS beat(12)-1.88%
EPS beat(16)9
Avg EPS beat(16)-1.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16%
EPS NQ rev (1m)-39.24%
EPS NQ rev (3m)-39.24%
EPS NY rev (1m)-20.17%
EPS NY rev (3m)-54.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.48 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.92
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-2.59
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS0
BVpS1.97
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -127.82% | ||
| ROE | -143.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-59.81%
ROA(5y)-63.82%
ROE(3y)-64.26%
ROE(5y)-70.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.15 | ||
| Quick Ratio | 7.15 | ||
| Altman-Z | -10.42 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.83%
EPS Next Y0.77%
EPS Next 2Y31.8%
EPS Next 3Y21.9%
EPS Next 5Y13.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-272.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-272.44%
OCF growth 3YN/A
OCF growth 5YN/A